Ahead of Solwers' Q2 report on 30 August, we update our estimates to reflect two acquisitions conduc...
Redeye comments on Modelon's Q2 2024 report, which was in line with our expectations.
Redeye comments on Flexion Mobile's Q2 2024 report, which was in line with our expectations.
Sales SEK 35m, EBIT SEK 13m, 37% margin, in line with ABGSCe Previously announced programme shut dow...
Redeye comments on Thunderful Group’s Q2’24 report, which came in better than expected in terms of s...
Q2 EBIT of SEK 34m, +41% vs. ABGSC but -21% vs. consensus AUM 2% above forecast, positive for revisi...
Redeye states that Q2 came in weaker than it had expected, although the reason continues to be a ver...
H1 2024 net Sales reached SEK204m, a 319% increase year-on-year, following the reverse acquisition o...
Taaleri's Q2 2024 results were well above LSEG Data & Analytics consensus and our expectations, main...
2024e estimates raised by 1-2% on order phasing We're above guidance midpoint but expect unchanged F...
Solid sales but slightly higher opex EBIT revised down by 4.
Redeye states that today’s ruling about a reversed decision from last year’s marksman hearing increa...
Redeye returns with a more detailed take on the Q2 report, and we make some estimate changes that pu...
Redeye is positively surprised to see Enviro receiving an additional milestone payment from the JV r...
Pharma Equity Group (“PEG” or “the Company”) presented a Q2-report characterized by further advancem...
Redeye comments on Amniotics' H1 report 2024, which will likely be its last before the merger with M...
Redeye concludes that the reported figures were overall stronger than we had forecasted.
Net sales were SEK5m higher than expected, with an EBITDA almost SEK3m higher than our estimate.
Sales and profitability were weaker than expected; however, Redeye views this half-year period as be...
Redeye sees a quarter demonstrating continued strong sales growth and an OPEX that is in line with o...
